Advertisement
Advertisement

AYTU

AYTU logo

AYTU BioPharma, Inc. Common Stock

2.60
USD
Sponsored
+0.02
+0.81%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

2.60

-0.01
-0.23%

AYTU Earnings Reports

Positive Surprise Ratio

AYTU beat 21 of 36 last estimates.

58%

Next Report

Next Week
Date of Next Report
Feb 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$12.42M
/
-$0.61
Implied change from Q1 26 (Revenue/ EPS)
-10.59%
/
-390.48%
Implied change from Q2 25 (Revenue/ EPS)
-23.45%
/
+134.62%

AYTU BioPharma, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, AYTU reported earnings of 0.21 USD per share (EPS) for Q1 26, beating the estimate of -0.23 USD, resulting in a 189.51% surprise. Revenue reached 13.89 million, compared to an expected 12.64 million, with a 9.83% difference. The market reacted with a +1.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 5 analysts forecast an EPS of -0.61 USD, with revenue projected to reach 12.42 million USD, implying an decrease of -390.48% EPS, and decrease of -10.59% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q1 2026, AYTU BioPharma, Inc. Common Stock reported EPS of $0.21, beating estimates by 189.51%, and revenue of $13.89M, 9.83% above expectations.
The stock price moved up 1.46%, changed from $2.06 before the earnings release to $2.09 the day after.
The next earning report is scheduled for Feb 03, 2026.
Based on 5 analysts, AYTU BioPharma, Inc. Common Stock is expected to report EPS of -$0.61 and revenue of $12.42M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement